POLARIS INSIGHTS

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock

Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.